From Scott Losermann's latest document.
"Moreover, although FDA approved Jakafi in 2019 for treatment of SR-aGVHD in adult
and pediatric patients 12 years and older based primarily upon the results of a pivotal, single-arm
clinical trial, this precedent cannot be applied to remestemcel-L. FDA accepted the results from
the single-arm clinical trial as the sole basis of efficacy only after considering several regulatory
factors regarding SR-aGVHD and prior clinical experience with Jakafi. Specifically, the FDA
reviewers explained that such reliance was appropriate “where the disease is life-threatening, there
are no approved therapies and no optimal therapy identified, the efficacy endpoint is objective, the
activity of the drug is established in other diseases, and there is a substantial safety database ….”27
Significantly, several of these factors clearly do not apply to remestemcel-L."
I agree to now get rid of Jakafi and replace it with a better efficacious treatment. Great suggestion Scott!!
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-5475
-
- There are more pages in this discussion • 12,346 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.17 |
Change
0.000(0.00%) |
Mkt cap ! $1.358B |
Open | High | Low | Value | Volume |
$1.15 | $1.20 | $1.15 | $2.025M | 1.729M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 31955 | $1.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 28063 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 13774 | 1.165 |
21 | 93138 | 1.160 |
16 | 96494 | 1.155 |
21 | 247391 | 1.150 |
8 | 146091 | 1.145 |
Price($) | Vol. | No. |
---|---|---|
1.170 | 35217 | 7 |
1.175 | 82384 | 11 |
1.180 | 88704 | 11 |
1.185 | 59954 | 6 |
1.190 | 70277 | 6 |
Last trade - 12.27pm 16/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, CEO / Non-Exec Director
James Graham / Dr Alan Dunton
CEO / Non-Exec Director
SPONSORED BY The Market Online